Shares of Dynavax Technologies Co. (NASDAQ:DVAX) have been assigned an average recommendation of “Hold” from the eight research firms that are presently covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation, two have given a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $27.40.
DVAX has been the topic of several analyst reports. BidaskClub cut Dynavax Technologies from a “sell” rating to a “strong sell” rating in a research report on Friday, January 19th. JPMorgan Chase & Co. cut Dynavax Technologies from an “overweight” rating to a “neutral” rating and decreased their price target for the company from $31.00 to $25.00 in a research report on Wednesday, February 14th. ValuEngine cut Dynavax Technologies from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Zacks Investment Research cut Dynavax Technologies from a “hold” rating to a “sell” rating in a research report on Wednesday, January 10th. Finally, Cowen restated a “buy” rating and issued a $30.00 price objective on shares of Dynavax Technologies in a research report on Wednesday, February 21st.
Shares of Dynavax Technologies (NASDAQ DVAX) traded down $0.20 on Tuesday, hitting $16.25. The stock had a trading volume of 321,844 shares, compared to its average volume of 1,401,142. Dynavax Technologies has a 12-month low of $5.00 and a 12-month high of $24.45. The company has a market capitalization of $999.23, a PE ratio of -8.83 and a beta of 1.05.
Dynavax Technologies (NASDAQ:DVAX) last announced its quarterly earnings results on Thursday, March 8th. The biopharmaceutical company reported ($0.43) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.11) by ($0.32). Dynavax Technologies had a negative net margin of 29,099.08% and a negative return on equity of 57.43%. The company had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.53 million. sell-side analysts expect that Dynavax Technologies will post -1.91 earnings per share for the current year.
In related news, VP David Louis Johnson sold 3,092 shares of the company’s stock in a transaction that occurred on Thursday, January 4th. The shares were sold at an average price of $18.60, for a total value of $57,511.20. Following the transaction, the vice president now directly owns 7,780 shares in the company, valued at $144,708. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider David F. Novack sold 2,121 shares of the company’s stock in a transaction that occurred on Friday, March 9th. The stock was sold at an average price of $17.97, for a total transaction of $38,114.37. Following the completion of the transaction, the insider now owns 77,192 shares in the company, valued at $1,387,140.24. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 39,427 shares of company stock worth $660,841. 2.90% of the stock is owned by company insiders.
Hedge funds have recently bought and sold shares of the stock. Royal Bank of Canada boosted its stake in Dynavax Technologies by 17.0% in the second quarter. Royal Bank of Canada now owns 20,454 shares of the biopharmaceutical company’s stock worth $198,000 after buying an additional 2,975 shares in the last quarter. Parametric Portfolio Associates LLC boosted its stake in Dynavax Technologies by 13.3% in the second quarter. Parametric Portfolio Associates LLC now owns 30,755 shares of the biopharmaceutical company’s stock worth $297,000 after buying an additional 3,604 shares in the last quarter. Voya Investment Management LLC boosted its stake in Dynavax Technologies by 26.3% in the second quarter. Voya Investment Management LLC now owns 21,403 shares of the biopharmaceutical company’s stock worth $207,000 after buying an additional 4,462 shares in the last quarter. Legal & General Group Plc boosted its stake in Dynavax Technologies by 36.1% in the third quarter. Legal & General Group Plc now owns 17,013 shares of the biopharmaceutical company’s stock worth $365,000 after buying an additional 4,512 shares in the last quarter. Finally, Vident Investment Advisory LLC boosted its stake in Dynavax Technologies by 3.1% in the third quarter. Vident Investment Advisory LLC now owns 150,258 shares of the biopharmaceutical company’s stock worth $3,231,000 after buying an additional 4,553 shares in the last quarter. Institutional investors own 72.52% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This article was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright law. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/04/07/dynavax-technologies-co-dvax-receives-27-40-average-target-price-from-brokerages.html.
Dynavax Technologies Company Profile
Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.